$DXCM

Brown Michael Jon sold $127K of DXCM

Brown Michael Jon (EVP Chief Legal Compliance Off) sold 1,700 shares of DEXCOM INC (DXCM) at $74.42 ($0.13M total) on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Brown Michael Jon
Published Jul 16, 2026, 9:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 16, 2026, 9:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DXCM
Neutral
high confidence
Mentioned
$DXCM
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DXCMNeutralLow
01

Why it matters

The disclosure updates insider ownership records but does not introduce new guidance, trial results, regulatory actions, or deal activity.

02

Market read

Traders may note the insider sale for positioning or sentiment, but it is unlikely to change the fundamental outlook.

03

What to watch

The transaction is explicitly under a pre-arranged 10b5-1 plan, which reduces interpretability versus discretionary selling.

Relevance 3/10Novelty 2/10Timing: Filed after-hours on 2026-07-16, reflecting a sale executed 2026-07-15.

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for DexCom.

Company-level read

Ticker impact

$DXCMNeutralHigh confidence
Context

DexCom Form 4 shows EVP Chief Legal Compliance Off Brown sold 1,700 shares at $74.42 on a 10b5-1 plan, totaling $126,514.

Expected impact

Low likelihood of a sustained price move; any reaction is likely short-lived and sentiment-driven.

Evidence & confidence

The filing is an open-market sale by an insider, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new company-specific operational or financial information.

Market effects

No meaningful read-across to the medical device or diabetes monitoring sector from a single routine 10b5-1 sale.

None.

None.

Counterpoint

Some traders may still treat insider selling as a weak sentiment signal, especially if multiple recent filings show net selling, but this article alone does not establish that pattern.

Key entities

  • DexCom

    Public company subject of the Form 4 insider transaction disclosure.

  • Michael Jon Brown

    EVP, Chief Legal Compliance Officer who executed the reported sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DXCMMed

A glucose sensor can be worn for up to 15.5 days. Dexcom's new monitor comes to Canada in November.

Dexcom's new G7 15 Day continuous glucose monitor, authorized by Health Canada, offers up to 15.5 days of wear and will be available in Canada in November. The company claims it is the longest-lasting and most accurate CGM system. Public and private reimbursement will be in place, making it accessible to eligible Canadians with diabetes. Dexcom aims to simplify glucose management with fewer sensor changes and reduced waste.

$DXCMMedAI 8/10

A glucose monitor added about five hours a day in target blood sugar range for people with type 2 diabetes

Dexcom G7 CGM technology showed significant improvement in glucose control for Type 2 diabetes patients, reducing A1C levels by 1.6% on average. The study, published in NEJM, found users spent 5 more hours daily in target glucose range. Benefits were consistent across diverse participants, including those on GLP-1 medications, according to Dexcom.

$DXCMMed

DexCom (DXCM) Tests Its Execution Story After Expanding Its CFO Role

DexCom (DXCM) promoted its CFO, Jereme Sylvain, to also serve as COO, expanding his role to include global operations and quality. The company's stock has seen volatility, with a 3.1% drop over the past week and a 30.2% gain year-to-date. Analysts suggest a fair value of $94.48, indicating a modest discount at the current price of $86.62.

$DXCMLow

Did COO Appointment Just Shift DexCom (DXCM) Investment Narrative?

DexCom (DXCM) appointed Jereme Sylvain as COO and Glenn Boehnlein to its board, focusing on execution, supply chain, and capital allocation. The company projects $6.8B revenue and $1.5B earnings by 2029, with analysts expecting 11.2% yearly growth. Investors watch leadership changes for impact on expansion and execution.